Mode
Text Size
Log in / Sign up
N/A Completed N=87

ReActiv8 Post Market Surveillance Registry

Source: ClinicalTrials.gov NCT03255200 ↗
Enrolled (actual)
87
Serious AEs
24.1%
Results posted
Oct 2024
Primary outcomePrimary: Low Back Pain - Numeric Pain Rating (NRS) Scale — 4.5; 4.3; 3.8; 3.4 units on a scale

Summary

To gather data on the long-term safety of ReActiv8 and identify any residual risks by reporting all Serious Adverse Device Effects as well as performance and health care utilization through two years post-implant.

Outcome Measures

OutcomeResultp-value
PRIMARY
Low Back Pain - Numeric Pain Rating (NRS) Scale
4.5; 4.3; 3.8; 3.4
SECONDARY
Serious Adverse Device Effects

Eligibility Criteria

Inclusion Criteria

  • Meet the Indications for ReActiv8
  • Willing to sign the Informed Consent for the Registry
  • Age ≥ 18 years

Exclusion Criteria

  • Subjects will be excluded from the Registry if they are contraindicated for ReActiv8.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03255200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search